Last reviewed · How we verify
High-Risk Smoldering Multiple Myeloma as monotherapy
Approved treatments
- Darzalex Faspro · Pfizer
Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- High-Risk Smoldering Multiple Myeloma as monotherapy patent landscape — cliff calendar, originator estates, attackable patents
- High-Risk Smoldering Multiple Myeloma as monotherapy treatment landscape brief
- High-Risk Smoldering Multiple Myeloma as monotherapy treatment updates RSS
Frequently asked questions about High-Risk Smoldering Multiple Myeloma as monotherapy
What drugs treat High-Risk Smoldering Multiple Myeloma as monotherapy?
Tracked treatments include Darzalex Faspro.
What is the treatment for High-Risk Smoldering Multiple Myeloma as monotherapy?
Standard treatment for High-Risk Smoldering Multiple Myeloma as monotherapy includes Darzalex Faspro. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: High-Risk Smoldering Multiple Myeloma as monotherapy patent cliff · High-Risk Smoldering Multiple Myeloma as monotherapy CI report
- Treatment: Darzalex Faspro · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing